M&T Bank Corporation Announces Dividend Declaration on Series A and Series C Preferred Stock
BUFFALO, N.Y., Jan. 18, 2018 /PRNewswire/ -- M&T Bank Corporation ("M&T") (NYSE: MTB) announced that it has declared quarterly cash dividends of $15.9375 per share on each of its Series A (NYSE: MTBPr) and Series C (NYSE: MTBPrC) preferred stock. The dividends will be payable February 15, 2018 to shareholders of record at the close of business on February 1, 2018.
About M&T Bank
M&T is a financial holding company headquartered in Buffalo, New York. M&T's principal banking subsidiary, M&T Bank, operates banking offices in New York, Maryland, New Jersey, Pennsylvania, Delaware, Connecticut, Virginia, West Virginia and the District of Columbia. Trust-related services are provided by M&T's Wilmington Trust-affiliated companies and by M&T Bank.
Pomerantz LLP is investigating claims on behalf of investors of Li Auto Inc. ("Li Auto" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Ralph & Pat Plumb, owners of the Brick Alley Pub, announced today that they've entered into an agreement to sell the Brick Alley Pub to The Heritage Restaurant Group, formerly 1899 Ventures, a Newport Rhode Island based restaurant group.
The Brick...
Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Pomerantz LLP is investigating claims on behalf of investors of Perion Network Ltd. ("Perion" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Pomerantz LLP is investigating claims on behalf of investors of TMC the metals company Inc. ("TMC" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. ...
Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
